Rebate Game Played By PBMs And Drug Makers Limits Biosimilar Competition
The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.
German pharmaceutical company sees great benefits from CIIE's spillover effect
STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...
FierceBiotech10d
Boehringer Ingelheim drops obesity drug from Gubra partnership
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
‘Sick day’ on the clock: CT Biopharma firm expands patient simulations to spark creativity, empathy
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
The Pharma Letter6d
Boehringer mental health tie-up worth up to $126.5 million to Broad Institute
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...
dvm36010d
Boehringer Ingelheim announces research and development facility expansion
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...
Surrozen Provides Third Quarter 2024 Financial Results and Business Update
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected ...
Zealand Pharma Announces Financial Results for the First Nine Months of 2024
No. 49 / 2024Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across ...
Zawya9d
Boehringer Ingelheim announces the appointment of new General Manager for Saudi Arabia, Gulf, and East Africa
Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure ...